Acadia Pharmaceuticals
ACAD
196 hedge funds and large institutions have $3.69B invested in Acadia Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 76 reducing their positions, and 30 closing their positions.
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
0.04% less ownership
Funds ownership: 95.91% → 95.87% (-0.04%)
0% less capital invested
Capital invested by funds: $3.7B → $3.69B (-$10.1M)
2% less funds holding
Funds holding: 199 → 196 (-3)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
30% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 76
66% less call options, than puts
Call options by funds: $38.8M | Put options by funds: $113M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$92.8M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$40.6M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.5M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$18.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$27.2M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$15.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.8M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$10.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.96M |
ACAD Hedge Fund Activity: Q2 2019 in Review
196 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2019, worth a combined $3.69B — down 0.27% from $3.7B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ACAD positions and 30 closed out — a net gain of 1 holder — while 53 added to existing stakes and 76 trimmed.
The largest buyer was Invesco, adding an estimated $92.8M. The largest seller was BlackRock, cutting an estimated $27.2M.
- 196 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2019, down from 199 in Q1 2019.
- Funds reported $3.69B of Acadia Pharmaceuticals stock for Q2 2019, down 0.27% quarter-over-quarter.
- 31 funds opened new Acadia Pharmaceuticals positions in Q2 2019 and 30 closed out, a net change of +1 holder.
- The largest Acadia Pharmaceuticals buyer in Q2 2019 was Invesco, an estimated $92.8M added.
- The largest Acadia Pharmaceuticals seller in Q2 2019 was BlackRock, an estimated $27.2M sold.
Based on aggregated 13F filings for Q2 2019.